Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain–Barré syndrome

Dyshidrotic eczema and seborrheic dermatitis‐like eczematous eruption following intravenous immunoglobulin therapy

“…9 When the IVIg therapy was readministered, most of the cases developed the same skin eruption. 8,10 Miyamoto 13 On the contrary, it has been suggested that IVIg may act like a B-cell superantigen, followed by selective activation of certain B cells. 14 Recently, the spectrum of possible side effects of IVIg has been enlarged by the report of eczematous reactions of unknown pathophysiologic mechanisms.…”

“…Rhee et al suggested that pompholyx may be due to a delayed‐type hypersensitivity in response to an unidentified substance within IVIg. The high perspiration rate of affected areas of the skin may enable accumulation of these potential allergens 13 . On the contrary, it has been suggested that IVIg may act like a B‐cell superantigen, followed by selective activation of certain B cells 14 …”

Integrated Chinese and western medicine for acute guillain-barré syndrome treatment

“…There were 28 subjects in the control group, including 19 males and 9 females, aged 10 to 67 (37.8±14.0) years, among which 22 cases had prodromal symptoms within 2 weeks before onset. The mean time since onset was 6.3 days [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. There were 5 mild cases, 17 moderate, and 6 severe cases.…”

“…Modern medical treatment majorly applies symptomatic and supportive therapies [5,6]. IVIg and plasma exchange are equally effective treatments for GBS; and there are some other special treatments, such as immunoglobulin therapy, plasmapheresis therapy, hormone therapy, and cerebrospinal fluid filtration [4,[7][8][9]. Currently, there is no specific drug for GBS treatment, and classical treatments are generally based on etiological programs, combined with neurotrophic and anti-inflammatory approaches.…”